4/A//SEC Filing
Snow David P. 4/A
Accession 0001415889-20-000638
CIK 0001035354other
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 2:30 PM ET
Size
9.8 KB
Accession
0001415889-20-000638
Insider Transaction Report
Form 4/AAmended
Snow David P.
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2020-01-30+6,250→ 6,250 total - Exercise/Conversion
Restricted Stock Units
2020-01-30−6,250→ 18,750 total→ Common Stock (6,250 underlying) - Tax Payment
Common Stock
2020-01-30$3.91/sh−2,045$7,996→ 4,205 total
Footnotes (5)
- [F1]Reflects the restricted stock units issued to the reporting person on January 30, 2019 which have partially vested and settled for shares of the issuer's common stock. The original Form 4 filed on January 31, 2020 is amended in its entirety by this Form 4 Amendment to provide the: (a) correct date the restricted stock units were first issued to the reporting person; and (b) correct disposition of the derivative securities.
- [F2]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F3]The original Form 4 filed on January 31, 2020 is amended by this Form 4 Amendment to correctly identify the nature of the transaction of the reporting person
- [F4]The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan.
- [F5]The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances.
Documents
Issuer
Eloxx Pharmaceuticals, Inc.
CIK 0001035354
Entity typeother
Related Parties
1- filerCIK 0001652972
Filing Metadata
- Form type
- 4/A
- Filed
- Mar 3, 7:00 PM ET
- Accepted
- Mar 4, 2:30 PM ET
- Size
- 9.8 KB